|
|
|
| Comparison of short-term efficacy between Albumin-Bound Paclitaxel and Docetaxel combined with Cisplatin in the treatment of locally middle and advanced nasopharyngeal carcinoma |
| LIU Guoying1 XIA Weixiong1 ZHANG Guangshun2 LYU Xing1 LI Wangzhong1 LIANG Hu1 GUO Xiang1 XIANG Yanqun1▲ |
1.Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangdong Province, Guangzhou 510060, China;
2.Department of Medical Physicists’ Room, Sun Yat-sen University Cancer Center, Guangdong Province, Guangzhou 510060, China |
|
|
|
Abstract Objective To compare the short-term efficacy of Albumin-Bound Paclitaxel combined with Cisplatin (AC) and Docetaxel combined with Cisplatin (DC) in the treatment of locally middle and advanced nasopharyngeal carcinoma. Methods From January 2016 to December 2019, the clinical data of stage Ⅲ-Ⅳa nasopharyngeal carcinoma patients who received AC or DC as induction chemotherapy from Sun Yat-sen University Cancer Center were collected retrospectively. After propensity score matching, there were 54 cases in each group. The short-term efficacy after induction chemotherapy and 3 months after completion of radio-chemotherapy were compared between the two groups, the disease progression and the incidence of adverse reaction in the two groups was observed. Results After induction chemotherapy and 3 months after completion of radio-chemotherapy, there were no significant differences in the total effective rate between two groups (P > 0.05). There was no significant difference in disease progression rate between the two groups (P ＞ 0.05). There was no significant differences in the toxicity and side effects of leukopenia, neutropenia, anemia and thrombocytopenia between the two groups (P > 0.05). Conclusion AC is well tolerated and effective in middle and advanced nasopharyngeal carcinoma, and the comparison of efficacy with DC still needs longer follow-up to be further confirmed.
|
|
|
|
|
|
| Cite this article: |
|
LIU Guoying1 XIA Weixiong1 ZHANG Guangshun2 LYU Xing1 LI Wangzhong1 LIANG Hu1 GUO Xiang1 XIANG Yanqun1▲. Comparison of short-term efficacy between Albumin-Bound Paclitaxel and Docetaxel combined with Cisplatin in the treatment of locally middle and advanced nasopharyngeal carcinoma[J]. 中国医药导报, 2021, 18(8): 90-93.
|
|
|
|
| URL: |
| http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I8/90 |
[1] Chen YP，Chan ATC，Le QT，et al. Nasopharyngeal carcinoma [J]. Lancet，2019，394（10192）：64-80.
[2] Li WF，Chen L，Sun Y，et al. Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma [J]. Chin J Cancer，2016，35（1）：94.
[3] Chua DT，Ma J，Sham JS，et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma：a pooled data analysis of two phase Ⅲ trials [J]. J Clin Oncol，2005，23（4）：1118-1124.
[4] Li Y，Tang LQ，Liu LT，et al. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chem-oradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents：A Matched Cohort Analysis [J]. Cancer Res Treat，2018，50（4）：1304-1315.
[5] Sun Y，Li WF，Chen NY，et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3，multicentre，randomised controlled trial [J]. Lancet Oncol，2016，17（11）：1509-1520.
[6] 冯庆，沈冰，黄瑞文.TPF或TP方案诱导化疗联合同步放化疗治疗局部晚期鼻咽癌的临床疗效[J].智慧健康，2020，6（10）：117-119.
[7] Hui EP，Ma BB，Leung SF，et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [J]. J Clin Oncol，2009，27（2）：242-249.
[8] Tang LL，Chen YP，Mao YP，et al. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era [J]. J Natl Compr Canc Netw，2017，15（7）：913-919.
[9] Colevas AD，Yom SS，Pfister DG，et al. NCCN Guidelines Insights：Head and Neck Cancers，Version 1. 2018 [J]. J Natl Compr Canc Netw，2018，16（5）：479-490.
[10] Tian Z，Zhang F，Li P，et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma [J]. BMC Cancer，2020，20（1）：698.
[11] 颜芳，应明真，陈龙佩，等.白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J].中国癌症杂志，2020，30（8）：632-635.
[12] Nyman DW，Campbell KJ，Hersh E，et al. Phase Ⅰ and pharmacokinetics trial of ABI-007，a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies [J]. J Clin Oncol，2005，23（31）：7785-7793.
[13] Alberts DS，Blessing JA，Landrum LM，et al. Phase Ⅱ trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer：A gynecologic oncology group study [J]. Gynecol Oncol，2012，127（3）：451-455.
[14] Ke LR，Xia WX，Qiu WZ，et al. A phase Ⅱ trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma [J]. Oral Oncol，2017， 70：7-13.
[15] Wang HY，Chang YL，To KF，et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma [J]. Chin J Cancer，2016，35：41.
[16] 阚红星，李洋，李晗，等.基于调强放疗鼻咽癌患者比较中国2008分期与UICC 8版分期异同[J].中华肿瘤防治杂志，2018，25（23）：1643-1648.
[17] de Kock I，Mirhosseini M，Lau F，et al. Conversion of Karnofsky Performance Status （KPS） and Eastern Cooperative Oncology Group Performance Status （ECOG） to Palliative Performance Scale （PPS），and the interchangeability of PPS and KPS in prognostic tools [J]. J Palliat Care，2013，29（3）：163-169.
[18] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[19] Zhang Y，Chen L，Hu GQ，et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma [J]. N Engl J Med，2019，381（12）：1124-1135.
[20] Zhong YH，Dai J，Wang XY，et al. Phase Ⅱ trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma [J]. Cancer Chemother Pharmacol，2013，71（6）：1577-1583.
[21] Kashiwada T，Saito Y，Terasaki Y，et al. Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer [J]. Jpn J Clin Oncol，2019，49（2）：165-173.
[22] Tan H，Hu J，Liu S. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer：a systematic review and meta-analysis [J]. Artif Cells Nanomed Biotechnol，2019，47（1）：268-277.
[23] Kotake M，Kuwako T，Imai H，et al. Phase Ⅱ Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer [J]. Chemotherapy，2020：1-8.
[24] Liu Y，Dong Y，Zhu H，et al. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer：A retrospective study [J]. Cancer Med，2020，9（4）：1365-1373.
[25] Schell A，Ley J，Wu N，et al. Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck [J]. Cancer Med，2015，4（4）：481-489. |
|
|
|
